Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
99pct
542d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2006 · year_end · Health Issues
Vaccine & immunization programs; product liability; influenza vaccine stockpiles & appropriations & safety: S.2554, S. 3678, H.R. 5533, H.R. 5647, S. 3708, S. 1880, H.R. 2863, H.R. 5587, H.R. 4245, S. 1821, S. 96, S. 3627, S. 843, H.r. 3970, S. 1826, S. 1437, S. 969, S. 3492, S. 1527, H.R. 3502
Client expense: Not reported · Firm income: $100,000
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2005 · year_end · Taxation/Internal Revenue Code
S. 96: A bill to target Federal funding for research and development, to amend section 1928 of the Social Security Act to encourage the production of influenza vaccines by eliminating the price cap applicable to the purchase of such vaccines under contracts entered into by the Secretary of Health and Human Services, to amend the Internal Revenue Code of 1986 to establish a tax credit to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry.H.R. 628, H.R. 813: To amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccing production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for the interests of the vaccine industry. S. 375, H.R. 628, H.R. 813: A bill to amend the Public Health Service Act to provide for an influenza vaccine awareness campaign, ensure a sufficient influenza vaccine supply, and prepare for an influenza pandemic or epidemic, to amend the Internal Revenue Code of 1986 to encourage vaccine production capacity, and for other purposes. Lobbied for incentives for the vaccine industry. S. 627: A bill to amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied for the R & D Tax credit. H.R. 1736: To amend the Internal Revenue Code of 1986 to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses. Lobbied for the R & D Tax credit. H.R. 2943, S. 1263: To amend the Small Business Act to establish eligibility requirements for business concerns to receive awards under the Small Business Innovation Research Program Lobbied for small business interests. H.R. 3154: To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, and for other purposes. Lobbied for incentives for the vaccine industry. H.R. 913: To direct the Securities and Exchange Commission to require enchanced disclosures of employee stock options, and to require a study on the economic impact of broad-based employee stock option plans, and for other purposes. Lobbied for the interests of the Biotech Medical Products industry. H.R. 1234: To amend the Internal Revenue Code of 1986 to require greater transparency of corporate tax accounting measures, to facilitate analysis of financial statements, to permit inspection of true corporate tax liability and understand the tax strategies undertaken by corporations, to discourage abusive tax sheltering activities, and to restore investor confidence in publicly traded corporations. Lobbied for the interest of the Biotech Medical products industry. S. 1008: A bill to amend the Internal Revenue Code of 1986 to add meningococcal vaccines to the list of taxable vaccines for purposes of the Vaccine Injury Compensation Trust Fund. Lobbied for incentives for the vaccine industry.
Client expense: Not reported · Firm income: $100,000
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE